FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3081056548> ?p ?o ?g. }

• W3081056548 abstract "Abstract Background Clinical trials have been conducted to clarify the beneficial effects of VD3 (1α,25-dihydroxy vitamin D3, also known as calcitriol) treatment in prostate cancer. However, the molecular mechanisms underlying these effects are not fully understood. Recent studies on IGFBP-3 have indicated its intracellular functions in cell growth and apoptosis. The aim of this study was to confirm the benefits of low-dose VD3 treatment and clarify the molecular mechanisms underlying these beneficial effects in prostate cancer cells. Methods The molecular effects of simultaneous treatment of LNCaP cells and their genetically modified cell lines with low concentration of docetaxel and VD3 were biologically and biochemically analyzed. To further determine the effects of VD3 treatment on IGFBP-3 induction system, cells were temporarily treated with VD3 in combination with a transcriptional inhibitor or protein synthesis inhibitor. Bcl-2 protein and its mRNA behavior were also observed in Igfbp-3 expression-modified LNCaP cells to determine the involvement of IGFBP-3 in the suppression of Bcl-2 by VD3 treatment. Results Changes in IGFBP-3 expression levels in LNCaP cells indicated that it mediated the inhibition of cell growth induced by VD3 treatment. IGFBP-3 was also found to be a mediator of the enhanced cytotoxicity of prostate cancer cells to VD3 in combination with the anti-cancer drug. We further identified the distinct property of the IGFBP-3 induction system, wherein temporal VD3 stimulation-induced prolonged IGFBP-3 expression and VD3 treatment-induced increase in IGFBP-3 expression were optimized based on the protein concentration rather than the mRNA concentration. Meanwhile, Bcl-2 expression was down-regulated by VD3 treatment in an IGFBP-3-independent manner. Conclusion These findings indicate the molecular mechanisms of IGFBP-3 induction stimulated by VD3 and IGFBP-3 independent Bcl-2 suppression by VD3 treatment in prostate cancer cells. The results could prompt a re-evaluation of VD3 usage in therapy for patients with prostate cancer." @default.
• W3081056548 created "2020-09-01" @default.
• W3081056548 creator A5009660351 @default.
• W3081056548 creator A5010146375 @default.
• W3081056548 creator A5024277823 @default.
• W3081056548 creator A5058919860 @default.
• W3081056548 creator A5067353567 @default.
• W3081056548 creator A5071309978 @default.
• W3081056548 creator A5079335123 @default.
• W3081056548 creator A5081960754 @default.
• W3081056548 date "2020-08-24" @default.
• W3081056548 modified "2023-10-17" @default.
• W3081056548 title "Molecular evidence of IGFBP-3 dependent and independent VD3 action and its nonlinear response on IGFBP-3 induction in prostate cancer cells" @default.
• W3081056548 cites W1964335024 @default.
• W3081056548 cites W1978402006 @default.
• W3081056548 cites W1986527803 @default.
• W3081056548 cites W1990389642 @default.
• W3081056548 cites W1992934249 @default.
• W3081056548 cites W2014418366 @default.
• W3081056548 cites W2018730905 @default.
• W3081056548 cites W2018868115 @default.
• W3081056548 cites W2019351879 @default.
• W3081056548 cites W2026644677 @default.
• W3081056548 cites W2040546807 @default.
• W3081056548 cites W2052596829 @default.
• W3081056548 cites W2061029286 @default.
• W3081056548 cites W2064536538 @default.
• W3081056548 cites W2065133740 @default.
• W3081056548 cites W2066888185 @default.
• W3081056548 cites W2084647824 @default.
• W3081056548 cites W2101305429 @default.
• W3081056548 cites W2115235864 @default.
• W3081056548 cites W2118889444 @default.
• W3081056548 cites W2136314815 @default.
• W3081056548 cites W2164895413 @default.
• W3081056548 cites W2170642071 @default.
• W3081056548 cites W2253893698 @default.
• W3081056548 cites W2463340802 @default.
• W3081056548 cites W2539436866 @default.
• W3081056548 cites W2605046576 @default.
• W3081056548 cites W2727380696 @default.
• W3081056548 cites W2790397185 @default.
• W3081056548 cites W2791688509 @default.
• W3081056548 cites W2802593900 @default.
• W3081056548 cites W2883905931 @default.
• W3081056548 cites W2900641549 @default.
• W3081056548 cites W2907538838 @default.
• W3081056548 cites W2937483840 @default.
• W3081056548 cites W641494006 @default.
• W3081056548 doi "https://doi.org/10.1186/s12885-020-07310-5" @default.
• W3081056548 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7446217" @default.
• W3081056548 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32831047" @default.
• W3081056548 hasPublicationYear "2020" @default.
• W3081056548 type Work @default.
• W3081056548 sameAs 3081056548 @default.
• W3081056548 citedByCount "5" @default.
• W3081056548 countsByYear W30810565482021 @default.
• W3081056548 countsByYear W30810565482023 @default.
• W3081056548 crossrefType "journal-article" @default.
• W3081056548 hasAuthorship W3081056548A5009660351 @default.
• W3081056548 hasAuthorship W3081056548A5010146375 @default.
• W3081056548 hasAuthorship W3081056548A5024277823 @default.
• W3081056548 hasAuthorship W3081056548A5058919860 @default.
• W3081056548 hasAuthorship W3081056548A5067353567 @default.
• W3081056548 hasAuthorship W3081056548A5071309978 @default.
• W3081056548 hasAuthorship W3081056548A5079335123 @default.
• W3081056548 hasAuthorship W3081056548A5081960754 @default.
• W3081056548 hasBestOaLocation W30810565483 @default.
• W3081056548 hasConcept C121608353 @default.
• W3081056548 hasConcept C126322002 @default.
• W3081056548 hasConcept C143998085 @default.
• W3081056548 hasConcept C190283241 @default.
• W3081056548 hasConcept C2779707156 @default.
• W3081056548 hasConcept C2779723316 @default.
• W3081056548 hasConcept C2780192828 @default.
• W3081056548 hasConcept C2781190966 @default.
• W3081056548 hasConcept C502942594 @default.
• W3081056548 hasConcept C55493867 @default.
• W3081056548 hasConcept C71924100 @default.
• W3081056548 hasConcept C86803240 @default.
• W3081056548 hasConcept C96232424 @default.
• W3081056548 hasConceptScore W3081056548C121608353 @default.
• W3081056548 hasConceptScore W3081056548C126322002 @default.
• W3081056548 hasConceptScore W3081056548C143998085 @default.
• W3081056548 hasConceptScore W3081056548C190283241 @default.
• W3081056548 hasConceptScore W3081056548C2779707156 @default.
• W3081056548 hasConceptScore W3081056548C2779723316 @default.
• W3081056548 hasConceptScore W3081056548C2780192828 @default.
• W3081056548 hasConceptScore W3081056548C2781190966 @default.
• W3081056548 hasConceptScore W3081056548C502942594 @default.
• W3081056548 hasConceptScore W3081056548C55493867 @default.
• W3081056548 hasConceptScore W3081056548C71924100 @default.
• W3081056548 hasConceptScore W3081056548C86803240 @default.
• W3081056548 hasConceptScore W3081056548C96232424 @default.
• W3081056548 hasFunder F4320334764 @default.
• W3081056548 hasIssue "1" @default.
• W3081056548 hasLocation W30810565481 @default.
• W3081056548 hasLocation W30810565482 @default.
• W3081056548 hasLocation W30810565483 @default.
• W3081056548 hasOpenAccess W3081056548 @default.

• next